Rein Therapeutics
RNTX
48 hedge funds and large institutions have $12.5M invested in Rein Therapeutics in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
29% more capital invested
Capital invested by funds: $9.76M → $12.5M (+$2.78M)
20% more funds holding
Funds holding: 40 → 48 (+8)
4.66% more ownership
Funds ownership: 36.43% → 41.08% (+4.7%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$2.17M |
| 2 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$325K |
| 3 |
ADEF
ABS Direct Equity Fund
Stamford,
Connecticut
|
+$172K |
| 4 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
+$138K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$173K |
| 2 |
EWA
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
-$35K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
-$26.8K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$17.2K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$12.6K |
RNTX Hedge Fund Activity: Q4 2025 in Review
48 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2025, worth a combined $12.5M — up 29% from $9.76M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RNTX positions and 4 closed out — a net gain of 9 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was Voss Capital, adding an estimated $2.17M. The largest seller was Prosight Management, cutting an estimated $173K.
- 48 institutional investors held Rein Therapeutics (RNTX) as of Q4 2025, up from 40 in Q3 2025.
- Funds reported $12.5M of Rein Therapeutics stock for Q4 2025, up 29% quarter-over-quarter.
- 13 funds opened new Rein Therapeutics positions in Q4 2025 and 4 closed out, a net change of +9 holders.
- The largest Rein Therapeutics buyer in Q4 2025 was Voss Capital, an estimated $2.17M added.
- The largest Rein Therapeutics seller in Q4 2025 was Prosight Management, an estimated $173K sold.
Based on aggregated 13F filings for Q4 2025.